Stockscreener 앱 받기
30.31
3.80%
1.11
시간 외 거래:
30.35
0.04
+0.13%
전일 마감가:
$29.20
열려 있는:
$29.45
하루 거래량:
483.09K
Relative Volume:
1.95
시가총액:
$3.71B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.74%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$28.39
$31.51
1주일 범위
$26.68
$31.51
52주 변동 폭
$24.51
$34.47
Parabilis Medicines Inc Stock (PBLS) Company Profile
Compare PBLS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
30.31 | 3.57B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Parabilis Medicines Inc 주식(PBLS)의 최신 뉴스
Leerink Partners Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $40 - Moomoo
Leerink initiates Parabilis Medicines stock with Outperform rating By Investing.com - Investing.com South Africa
The biggest biotech funding rounds in June 2026 - Labiotech.eu
PBLS Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Analyst Initiates Buy on Parabilis, Citing First-in-Class Wnt Inhibitor Zolucatidine and Strong Cash Runway - TipRanks
Michael Schmidt Initiates Buy on Parabilis Medicines, Citing Helicon Platform and Zolucatetide as Key Value Drivers with $40 Price Target - TipRanks
BofA Securities initiates Parabilis Medicines stock coverage with buy rating - Investing.com
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Guggenheim initiates Parabilis Medicines stock with buy rating - Investing.com
PBLS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Large VC financings improve in H1 2026 - BioWorld News
Nasdaq Delivers the Strongest First Half in U.S. Exchange History as Public Markets Momentum Builds - Moomoo
Mass. biotech IPO proceeds near $3.2B, close in on pandemic-era record pace - The Business Journals
Insider Stock Purchases: June 29, 2026 - Quiver Quantitative
[Form 4] Parabilis Medicines, Inc. Insider Trading Activity - Stock Titan
Parabilis Medicines (PBLS) holder reports 527,070-share Series F position - Stock Titan
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
PBLS|Parabilis Medicines Ord Shs|Price:28.800|Chg%:2.44 - TradingKey
Price to earnings forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Price to book forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
PBLS: Parabilis Medicines, Inc.12 Month EPS - Zacks Investment Research
Price to sales forward of Parabilis Medicines, Inc. – BOATS:PBLS - TradingView
Parabilis Medicines (PBLS) Insider Trading Activity 2026 - MarketBeat
Enterprise value to EBIT forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Parabilis Medicines (PBLS) Stock Trends and Sentiment 2026 - MarketBeat
Parabilis Medicines, Inc. (PBLS) Book Value (Per Share) - Zacks Investment Research
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Total operating expenses of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? - The Globe and Mail
PBLSParabilis Medicines Inc Forecast, Target Price - Finviz
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
RA Capital Management Discloses Investment at Parabilis Medicines with 23.8% Stake - TradingView
[SCHEDULE 13D] Parabilis Medicines, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
PBLS SEC FilingsPARABILIS MEDICINES INC 10-K, 10-Q, 8-K Forms - Stock Titan
PBLS Technical Analysis & Stock Price Forecast - Intellectia AI
PBLS PE Ratio & Valuation, Is PBLS Overvalued - Intellectia AI
PBLS | Parabilis Medicines, Inc. Common Institutional Ownership - Quiver Quantitative
Apothecary Capital, tied to Parabilis (PBLS) director, buys 17,500 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Parabilis Medicines stock jumps on insider buying activity By Investing.com - Investing.com Nigeria
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines stock jumps on insider buying activity - Investing.com
PBLS | Parabilis Medicines, Inc. Common Insider Trading - Quiver Quantitative
RA Capital funds lift Parabilis Medicines (PBLS) common equity exposure - Stock Titan
Parabilis Medicines (PBLS) director converts preferred stock into common around IPO - Stock Titan
Parabilis (PBLS) director-linked LLC makes open-market buy of 12,500 shares - Stock Titan
Parabilis Medicines (PBLS) director converts Series F preferred into common in IPO - Stock Titan
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline - Yahoo Finance
PBLS : Parabilis Medicines, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Parabilis Medicines Inc (PBLS) 재무 분석
Parabilis Medicines Inc (PBLS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Parabilis Medicines Inc 주식 (PBLS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SEBULSKY ALAN | Director |
Jun 15 '26 |
Buy |
26.49 |
9,065 |
240,135 |
30,000 |
| SEBULSKY ALAN | Director |
Jun 12 '26 |
Buy |
27.67 |
8,435 |
233,393 |
20,935 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 11 '26 |
Buy |
20.00 |
21,188,750 |
423,775,000 |
26,285,093 |
| SEBULSKY ALAN | Director |
Jun 11 '26 |
Buy |
20.00 |
12,500 |
250,000 |
12,500 |
1.18%
2.48%
자본화:
|
볼륨(24시간):